The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Increased Platelet Aggregability Associated With Platelet GPIIIa Pl A2 Polymorphism : The Framingham Offspring Study
Abstract
Abstract —The platelet glycoprotein IIb/IIIa (GP IIb/IIIa) plays a pivotal role in platelet aggregation. Recent data suggest that the Pl A2 polymorphism of GPIIIa may be associated with an increased risk for cardiovascular disease. However, it is unknown if there is any association between this polymorphism and platelet reactivity. We determined GP IIIa genotype and platelet reactivity phenotype data in 1422 subjects from the Framingham Offspring Study. Genotyping was performed using PCR-based restriction fragment length polymorphism analysis. Platelet aggregability was evaluated by the Born method. The threshold concentrations of epinephrine and ADP were determined. Allele frequencies of Pl A1 and Pl A2 were 0.84 and 0.16, respectively. The presence of 1 or 2 Pl A2 alleles was associated with increased platelet aggregability as indicated by incrementally lower threshold concentrations for epinephrine and ADP. For epinephrine, the mean concentrations were 0.9 μmol/L (0.9 to 1.0) for homozygous Pl A1 , 0.7 mmol/L (0.7 to 0.9) for the heterozygous Pl A1 / Pl A2 , and 0.6 μmol/L (0.4 to 1.0) for homozygous Pl A2 individuals, P =0.009. The increase in aggregability induced by epinephrine remained highly significant ( P =0.007) after adjustment for covariates. For ADP-induced aggregation, the respective mean concentrations were 3.1 μmol/L (3.0 to 3.2), 3.0 μmol/L (2.9 to 3.2), and 2.8 μmol/L (2.4 to 3.3); P =0.19 after adjustment for covariates. Our findings indicate that molecular variants of the gene encoding GP IIIa play a role in platelet reactivity in vitro. Our observations are compatible with and provide an explanation for the reported association of the Pl A2 allotype with increased risk for cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longitudinal data analysis using generalized linear models
LIANG, K.-Y., & ZEGER, S. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.13 · Cited by 18,550
Applied Regression Analysis and Other Multivariable Methods
Walker, E. (1989) · Technometrics · doi:10.1080/00401706.1989.10488486 · Cited by 8,538
Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal
BORN, G. V. R. (1962) · Nature · doi:10.1038/194927b0 · Cited by 4,294
Prevalence of Total Coronary Occlusion during the Early Hours of Transmural Myocardial Infarction
DeWood, M. A., Spores, J., Notske, R., Mouser, L. T., Burroughs, R., Golden, M. S., & Lang, H. T. (1980) · New England Journal of Medicine · doi:10.1056/nejm198010163031601 · Cited by 2,740
AN INVESTIGATION OF CORONARY HEART DISEASE IN FAMILIES
KANNEL, W. B., FEINLEIB, M., McNAMARA, P. M., GARRISON, R. J., & CASTELLI, W. P. (1979) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112813 · Cited by 1,645
Mittleman, M. A., Maclure, M., Tofler, G. H., Sherwood, J. B., Goldberg, R. J., & Muller, J. E. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312023292301 · Cited by 1,431
Self-citationGenetic Susceptibility to Death from Coronary Heart Disease in a Study of Twins
Marenberg, M. E., Risch, N., Berkman, L. F., Floderus, B., & de Faire, U. (1994) · New England Journal of Medicine · doi:10.1056/nejm199404143301503 · Cited by 1,255
Davies, M. J., Richardson, P. D., Woolf, N., Katz, D. R., & Mann, J. (1993) · Heart · doi:10.1136/hrt.69.5.377 · Cited by 1,127
Tofler, G. H., Brezinski, D., Schafer, A. I., Czeisler, C. A., Rutherford, J. D., Willich, S. N., Gleason, R. E., Williams, G. H., & Muller, J. E. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706113162405 · Cited by 1,072
Self-citationTopol, E., Califf, R., Weisman, H., Ellis, S., Tcheng, J., Worley, S., Ivanhoe, R., George, B., Fintel, D., Weston, M., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90007-8 · Cited by 838
The RISC Group (1990) · The Lancet · doi:10.1016/0140-6736(90)92336-g · Cited by 781
Madden, C. (1991) · Annals of Emergency Medicine · doi:10.1016/s0196-0644(05)81237-5 · Cited by 691
Weiss, E. J., Bray, P. F., Tayback, M., Schulman, S. P., Kickler, T. S., Becker, L. C., Weiss, J. L., Gerstenblith, G., & Goldschmidt-Clermont, P. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604253341703 · Cited by 689
Platelet Hyperreactivity and Prognosis in Survivors of Myocardial Infarction
Trip, M. D., Cats, V. M., van Capelle, F. J. L., & Vreeken, J. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005313222201 · Cited by 617
Localization of an Arg-Gly-Asp Recognition Site Within an Integrin Adhesion Receptor
D'Souza, S. E., Ginsberg, M. H., Burke, T. A., Lam, S. C.-T., & Plow, E. F. (1988) · Science · doi:10.1126/science.3262922 · Cited by 395
Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab thrombolytic therapy
Kleiman, N. S., Ohman, E. M., Califf, R. M., George, B. S., Kereiakes, D., Aguirre, F. V., Weisman, H., Schaible, T., & Topol, E. J. (1993) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(93)90041-x · Cited by 301
Inhibition of fibrinogen binding to GP IIb-IIIa by a GP IIIa peptide
Charo, I. F., Nannizzi, L., Phillips, D. R., Hsu, M. A., & Scarborough, R. M. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52310-3 · Cited by 219
Carter, A. M., Ossei‐Gerning, N., Wilson, I., & Grant, P. J. (1997) · Circulation · doi:10.1161/01.cir.96.5.1424 · Cited by 160
The power of identity-by-state methods for linkage analysis.
Bishop, D. T., & Williamson, J. (1990) · PubMed · Cited by 145
PlA2 polymorphism and efficacy of aspirin
Cooke, G. E., Bray, P. F., Hamlington, J. D., Pham, D., & Goldschmidt‐Clermont, P. J. (1998) · The Lancet · doi:10.1016/s0140-6736(05)79320-x · Cited by 131
Winther, K., Hillegass, W. B., Tofler, G. H., Jimenez, A., Brezinski, D. A., Schafer, A. I., Loscalzo, J., Williams, G. H., & Muller, J. E. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)90359-7 · Cited by 87
Self-citationGlycoprotein IIIa polymorphism and risk of myocardial infarction
Samani, N. J., & Lodwick, D. (1997) · Cardiovascular Research · doi:10.1016/s0008-6363(96)00222-2 · Cited by 65
Platelet Glycoprotein IIIaPlAPolymorphism and Myocardial Infarction
Marian, A. J., Brugada, R., & Kleiman, N. S. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351418 · Cited by 58
Clues to the death of an Olympic champion
Goldschmidt‐Clermont, P. J., Shear, W., Schwartzberg, J., Varga, C. F., & Bray, P. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91652-9 · Cited by 28
(1996) · Transfusion Medicine Reviews · doi:10.1016/s0887-7963(96)80015-0 · Cited by 23
Cited by
Fontana, P., Dupont, A., Gandrille, S., Bachelot-Loza, C., Reny, J.-L., Aiach, M., & Gaussem, P. (2003) · Circulation · doi:10.1161/01.cir.0000085073.69189.88 · Cited by 425
Platelet GP IIIa Pl A Polymorphisms Display Different Sensitivities to Agonists
Michelson, A. D., Furman, M. I., Goldschmidt-Clermont, P., Mascelli, M. A., Hendrix, C., Coleman, L., Hamlington, J., Barnard, M. R., Kickler, T., Christie, D. J., et al. (2000) · Circulation · doi:10.1161/01.cir.101.9.1013 · Cited by 310
Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions
Undas, A., Brummel-Ziedins, K. E., & Mann, K. G. (2007) · Blood · doi:10.1182/blood-2006-01-010645 · Cited by 254
Diagnosis and Treatment of Heart Disease: Are Women Different From Men?
Xhyheri, B., & Bugiardini, R. (2010) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2010.07.004 · Cited by 56
Metadata
- Authors
- Feng, D., Lindpaintner, K., Larson, M. G., Rao, V. S., O’Donnell, C. J., Lipinska, I., Schmitz, C., Sutherland, P. A., Silbershatz, H., D’Agostino, R. B., Muller, J. E., Myers, R. H., Levy, D., & Tofler, G. H.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 1999-04
- Volume
- 19
- Issue
- 4
- Pages
- 1142-1147
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2615965030
- Cited by
- 260
- References
- 25
- FWCI
- 10.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.